These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33772143)

  • 1. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
    DiNardo CD; Stein EM; Pigneux A; Altman JK; Collins R; Erba HP; Watts JM; Uy GL; Winkler T; Wang H; Choe S; Liu H; Wu B; Kapsalis SM; Roboz GJ; de Botton S
    Leukemia; 2021 Nov; 35(11):3278-3281. PubMed ID: 33772143
    [No Abstract]   [Full Text] [Related]  

  • 2. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Ock CY; Seo H; Kim DY; Min BJ; Park Y; Cheong HS; Kim HL; Song EY; Kim I; Yoon SS; Kim JH; Koh Y
    Leuk Lymphoma; 2019 Jul; 60(7):1775-1781. PubMed ID: 30507323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
    J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Donker ML; Ossenkoppele GJ
    Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
    Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
    Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Rasche A; Mason EF; Strickland SA; Byrne M; Ferrell PB
    Br J Haematol; 2021 Sep; 194(5):927-931. PubMed ID: 34096047
    [No Abstract]   [Full Text] [Related]  

  • 14. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
    DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML; Sallman DA; Hossain M; Marchione DM; Bai X; Patel PA; Kapsalis SM; Garcia-Manero G; Fathi AT
    Blood Adv; 2024 Aug; 8(15):4209-4220. PubMed ID: 38640348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
    Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
    Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Drug Approved for Patients with Refractory AML and Mutation in the IDH1 Gene.
    Aschenbrenner DS
    Am J Nurs; 2018 Nov; 118(11):20-21. PubMed ID: 30358592
    [No Abstract]   [Full Text] [Related]  

  • 17. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP; Mannis GN; Pollyea DA; Stein AS; Uy GL; Watts JM; Fathi AT; Kantarjian HM; Tallman MS; Choe S; Dai D; Fan B; Wang H; Zhang V; Yen KE; Kapsalis SM; Hickman D; Liu H; Agresta SV; Wu B; Attar EC; Stone RM
    Blood; 2020 Feb; 135(7):463-471. PubMed ID: 31841594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib and ivosidenib in AML.
    Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
    Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
    Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.